Neumora Therapeutics, Inc. Common Stock
NMRA
Rank in Stocks
#21554
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company... Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Share Price
$0.3339
Last synced: 2026-11-20
Market Cap
$62.74M
Change (1 day)
-3.78%
Change (1 year)
-85.67%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Neumora Therapeutics, Inc. Common Stock (NMRA)
Category
Healthcare
Number of shares outstanding for Neumora Therapeutics, Inc. Common Stock (NMRA)
Number of shares outstanding as of June 2026: 185.16M
According to Neumora Therapeutics, Inc. Common Stock's latest financial reports, its current number of shares outstanding is 185.16M. At the end of 2025 the company had 163.39M shares outstanding. The number of shares outstanding usually changes with stock splits and share buybacks.
Shares outstanding history for Neumora Therapeutics, Inc. Common Stock (NMRA) from 2020 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 185.16M | 13.33% |
| 2025 | 163.39M | 2.52% |
| 2024 | 159.38M | 0.34% |
| 2023 | 158.83M | 4.53% |
| 2022 | 151.95M | 0.00% |
| 2021 | 151.95M | 0.00% |
| 2020 | 151.95M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.50M | 36.91% |
US
|
|
| 401.00M | 116.57% |
US
|
|
| 478.91M | 158.64% |
AU
|
|
| 0.00 | -100.00% |
BE
|
|
| 62.74M | -66.12% |
NL
|
Questions about Neumora Therapeutics, Inc. Common Stock's number of shares outstanding
What is Neumora Therapeutics, Inc. Common Stock's number of shares outstanding?
Neumora Therapeutics, Inc. Common Stock's number of shares outstanding is 185.16M, as of Jun 2026.
What was Neumora Therapeutics, Inc. Common Stock's number of shares outstanding in 2025?
In 2025, Neumora Therapeutics, Inc. Common Stock's number of shares outstanding was 163.39M, 2.52% more than in 2024 (159.38M).
How has Neumora Therapeutics, Inc. Common Stock's number of shares outstanding changed since 2020?
From 2020 to 2025, Neumora Therapeutics, Inc. Common Stock's number of shares outstanding went from 151.95M to 163.39M, an average growth of 1.46% a year.